Sunshine Biopharma (SBFM) Depreciation & Amortization (IS) (2016 - 2024)
Sunshine Biopharma (SBFM) has disclosed Depreciation & Amortization (IS) for 7 consecutive years, with $42618.0 as the latest value for Q1 2024.
- For the quarter ending Q1 2024, Depreciation & Amortization (IS) rose 22.78% year-over-year to $42618.0, compared with a TTM value of $83911.0 through Mar 2024, up 76.49%, and an annual FY2024 reading of $223527.0, up 49.87% over the prior year.
- Depreciation & Amortization (IS) was $42618.0 for Q1 2024 at Sunshine Biopharma, up from $34710.0 in the prior quarter.
- Across five years, Depreciation & Amortization (IS) topped out at $42618.0 in Q1 2024 and bottomed at $3110.0 in Q1 2022.
- Average Depreciation & Amortization (IS) over 3 years is $26812.7, with a median of $34710.0 recorded in 2023.
- The sharpest move saw Depreciation & Amortization (IS) soared 1016.08% in 2023, then rose 22.78% in 2024.
- Year by year, Depreciation & Amortization (IS) stood at $3110.0 in 2022, then skyrocketed by 1016.08% to $34710.0 in 2023, then increased by 22.78% to $42618.0 in 2024.
- Business Quant data shows Depreciation & Amortization (IS) for SBFM at $42618.0 in Q1 2024, $34710.0 in Q1 2023, and $3110.0 in Q1 2022.